Peptides for weight loss: what people mean, what works, and what is still a mouse result

Search “peptides for weight loss” and you land in two different worlds that share one word. In the first are prescription drugs that happen to be peptides, semaglutide and tirzepatide, tested in trials with thousands of people. In the second are compounds discussed and sold online, such as MOTS-c and 5-Amino-1MQ, whose reputations rest mostly on mouse studies. Between them sits retatrutide, an investigational drug with real human trial data that people are already buying outside any approval. This guide puts all of them on one scale. For each, it asks what the compound is, what the studies measured and in whom, what the side effects look like, what it costs, and what people online are actually doing with it. Every research statement links to its primary source, and the community section is kept separate from the evidence.

What are peptides for weight loss?

Peptides for weight loss are short chains of amino acids, or compounds marketed alongside them, that people use to lose fat, most often by reducing appetite. The term is loose. It covers approved drugs that copy gut hormones, investigational drugs still in trials, and research compounds sold online with little or no human data. One popular item on the list, 5-Amino-1MQ, is not a peptide at all.

The useful way to sort them is by evidence, not by label:

• Approved peptide drugs. Semaglutide (Wegovy, and Ozempic for diabetes) and tirzepatide (Zepbound, and Mounjaro for diabetes). These mimic the gut hormones GLP-1 and, for tirzepatide, GIP. Our explainer on how GLP-1 medications work for weight loss covers the mechanism in detail.
• An investigational peptide drug. Retatrutide, which adds a third hormone target, glucagon, and has posted phase 3 results.
• Research compounds. MOTS-c, a 16-amino-acid peptide made by mitochondria, and 5-Amino-1MQ, a small molecule that blocks an enzyme called NNMT. Both are sold in the same “weight loss” categories online.

Are peptides the same as Ozempic?

Ozempic is a peptide, but most products sold as “peptides” are not Ozempic. Semaglutide, the active ingredient in Ozempic and Wegovy, is a GLP-1 receptor agonist, a modified copy of the gut hormone glucagon-like peptide-1 (Wegovy label, DailyMed). The research peptides marketed for fat loss, such as MOTS-c, work through different pathways and have not been tested in the large human trials that semaglutide passed. Tesamorelin is a different case again: a growth-hormone-releasing peptide whose label names abdominal fat in adults with HIV and calls it weight neutral, covered in tesamorelin for belly fat. So “peptides” and “Ozempic” overlap, but the word alone tells you nothing about how much evidence sits behind a given product.

How do peptides work for weight loss?

Most weight-loss peptides with human data work by acting on gut-hormone receptors that reduce appetite and slow stomach emptying, so people eat less (Wegovy label). Semaglutide acts on one receptor (GLP-1), tirzepatide on two (GIP and GLP-1) (Jastreboff et al., 2022), and retatrutide on three (GIP, GLP-1 and glucagon) (Jastreboff et al., 2023).

The research compounds pitch a different idea: changing how cells handle energy rather than how hungry you are. In the founding lab and mouse work, MOTS-c acted mainly on skeletal muscle and led to activation of AMPK, the cell’s energy sensor (Lee et al., 2015). 5-Amino-1MQ blocks NNMT, which in cultured fat cells raised NAD+ and suppressed fat building (Neelakantan et al., 2018). Those mechanisms are real in the lab. Whether they move the scale in people has not been shown.

The evidence, compound by compound

Ranked from the strongest human data to the weakest, here is what each compound’s studies actually measured.

Semaglutide: approved drug, large human trials

Semaglutide has the evidence level of an approved drug with labeled use for weight management. In the STEP 1 trial, 1,961 adults without diabetes took weekly semaglutide or placebo for 68 weeks alongside lifestyle changes; average weight change was -14.9% against -2.4% on placebo, and about half the semaglutide group lost 15% or more (Wilding et al., 2021). The Wegovy label approves it to reduce excess body weight and keep it off in adults and adolescents 12 and older with obesity, and in adults with overweight plus a weight-related condition (Wegovy label).

Tirzepatide: approved drug, larger average loss

Tirzepatide also has the evidence level of an approved drug with labeled use. In SURMOUNT-1, 2,539 adults without diabetes took one of three weekly doses or placebo for 72 weeks; average weight change was -15.0%, -19.5% and -20.9% across the doses, against -3.1% on placebo (Jastreboff et al., 2022). Our comparison of semaglutide versus tirzepatide covers the head-to-head trial, brands and differences.

Retatrutide: investigational, phase 3 results announced

Retatrutide’s evidence level is large randomized human trials, with the caveat that the phase 3 results so far are company announcements. In the published phase 2 trial, 338 adults lost an average of 24.2% of body weight at 48 weeks on the highest dose, against 2.1% on placebo (Jastreboff et al., 2023). In the phase 3 TRIUMPH-1 trial, Lilly reported an average loss of 28.3% at 80 weeks on the 12 mg dose, against 2.2% on placebo, using an estimate that assumes everyone stayed on treatment; counting everyone regardless of adherence, the figure was 25.0% (Eli Lilly, May 21, 2026). It is not approved. The Treatment Report’s retatrutide overview covers the full trial program.

Oral options: one peptide pill, one non-peptide pill

The oral weight-loss options with human data are approved drugs, and only one of them is a peptide. The Wegovy pill, a once-daily oral form of semaglutide, was approved in December 2025; in the 64-week OASIS 4 trial of 307 adults, average weight loss was 16.6% if everyone stayed on treatment and 13.6% regardless of adherence, against 2.7% and 2.4% on placebo (Novo Nordisk, December 22, 2025). Foundayo (orforglipron), approved in April 2026, is described by its maker as a “small molecule (non-peptide)” oral GLP-1 drug; in the 72-week ATTAIN-1 trial, people on the highest dose who stayed on treatment lost an average of 12.4% against 0.9% on placebo, and 11.1% against 2.1% regardless of adherence (Eli Lilly, April 1, 2026).

MOTS-c: mouse studies, one human trial recruiting

MOTS-c’s evidence level is mostly animal and cell studies, plus human biomarker observations. The founding study reported that MOTS-c “prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity” in mice (Lee et al., 2015). A later study found it improved physical performance in young, middle-aged and old mice, and that in humans, exercise raises the body’s own MOTS-c in muscle and blood (Reynolds et al., 2021). That second finding shows exercise raising MOTS-c, not MOTS-c replacing exercise. On the human treatment side, a placebo-controlled phase 2a trial of MOTS-c in an estimated 120 adults with prediabetes and overweight or obesity began recruiting in February 2026; its primary outcomes are insulin sensitivity at 12 weeks and adverse events, not weight, and it has no results yet (ClinicalTrials.gov, NCT07505745). Our sister site covers what the MOTS-c metabolic research shows in depth, and our guide to MOTS-c for weight loss checks the visceral-fat claim against the mouse studies.

5-Amino-1MQ: cell and mouse studies only

5-Amino-1MQ’s evidence level is cell and mouse studies, with no human trials. In the founding study, nine obese mice given the compound by injection three times a day for 11 days lost 5.1% of body weight while controls gained 1.4%, and food intake did not differ, which the authors read as a metabolic rather than appetite effect (Neelakantan et al., 2018). A 2024 study in aged mice reported about 40% greater grip strength in treated sedentary mice; its authors disclose that the senior author founded Ridgeline Therapeutics, which develops NNMT inhibitors, and that two co-authors work there (Dimet-Wiley et al., 2024). A search of the ClinicalTrials.gov registry on October 12, 2026 for “5-amino-1MQ” and “5-amino-1-methylquinolinium” returned no registered studies. The Treatment Report’s 5-Amino-1MQ overview explains the chemistry and the full mouse record, and what those studies recorded about safety, including poor oral absorption in mice, is in our guide to 5-Amino-1MQ side effects and evidence.

Peptides for weight loss, side by side

The table ranks the main compounds by the strength of their human weight-loss evidence. Weight-loss figures are averages on the highest dose studied, compared with placebo, and come from the trials linked in the sections above.

What are the best peptides for weight loss?

If “best” means the most human evidence, the answer is the approved peptide drugs: tirzepatide and semaglutide, with retatrutide close behind on announced results but not yet approved. Those three have randomized trials in thousands of people showing average losses from about 15% to 28% (Wilding et al., 2021; Jastreboff et al., 2022; Eli Lilly, May 21, 2026). MOTS-c and 5-Amino-1MQ cannot be ranked on weight loss in people because no human weight-loss result exists for either. “Most talked about” and “best supported” are different lists, and the research compounds sit high on the first and low on the second.

Do peptides work for weight loss?

Some do, and the evidence is strong for those: the approved GLP-1 peptide drugs reliably produced double-digit average weight loss in large placebo-controlled trials. For the research peptides the honest answer is unknown, because they have not been tested for weight loss in people. A mouse losing 5% of its weight in 11 days (Neelakantan et al., 2018) is a reason to study a compound, not evidence that it works in a person. Averages also hide spread: even in TRIUMPH-1, 45.3% of people on the top dose lost 30% or more, which means most did not (Eli Lilly, May 21, 2026).

What are oral peptides for weight loss?

The only approved oral peptide for weight loss is the Wegovy pill, a daily tablet form of semaglutide. Its maker describes it as the first oral GLP-1 medicine for obesity in the US (Novo Nordisk, December 22, 2025). Two other pills often filed under “oral peptides” are not peptides: Foundayo is a non-peptide small molecule, and 5-Amino-1MQ, sold as an oral tablet, is also a small molecule. We found no published human study of how well 5-Amino-1MQ is absorbed when swallowed. The 2018 paper’s cell-based tests predicted good oral absorption, but its mouse experiment gave the compound by injection under the skin (Neelakantan et al., 2018), as did the 2024 aged-mouse study (Dimet-Wiley et al., 2024).

What are the side effects of peptides for weight loss?

The side effects of the approved and investigational peptide drugs are mainly gastrointestinal: nausea, diarrhea, vomiting and constipation, occurring mainly while the dose is being raised (Jastreboff et al., 2022). In STEP 1, nausea and diarrhea were the most common events with semaglutide, mostly mild to moderate, and 4.5% stopped because of gut effects against 0.8% on placebo (Wilding et al., 2021). The Wegovy label adds warnings for pancreatitis, gallbladder disease, low blood sugar in people on insulin or similar drugs, kidney injury, raised heart rate and suicidal thoughts, and a boxed warning because semaglutide caused thyroid C-cell tumors in rodents (Wegovy label). Our guide to GLP-1 side effects and how to manage them covers each one.

Retatrutide showed the same gut pattern: in TRIUMPH-1, nausea rose with dose, affecting 28.6% to 42.4% across doses against 14.8% on placebo. It also produced dysesthesia, an abnormal skin sensation, in 5.1% to 12.5% against 0.9% on placebo, and 11.3% stopped on the top dose because of adverse events against 4.9% on placebo (Eli Lilly, May 21, 2026). For MOTS-c and 5-Amino-1MQ, there is no human side-effect data to report; the 2018 mouse study reported no overt signs of toxicity in nine obese mice over 11 days (Neelakantan et al., 2018), which is not a human safety profile.

Are peptides safe for weight loss?

The approved peptide drugs have known, labeled risks that a prescriber monitors, and their safety has been studied in thousands of people over more than a year. The research compounds have no human safety record, so their safety for weight loss is simply unknown. Product quality adds a separate layer: compounds made outside the approved drug supply can vary in what they contain, a point clinicians raised about gray-market retatrutide, where users cannot know the dose or purity of what they inject (The Guardian, August 31, 2026).

What are the negatives of taking peptides?

The main negatives are side effects, cost, unknown long-term effects for the newer compounds, and what happens when you stop. In SURMOUNT-1, adverse events, most often gastrointestinal, led 4.3% to 7.1% of people on tirzepatide to stop treatment, against 2.6% on placebo (Jastreboff et al., 2022). For MOTS-c and 5-Amino-1MQ, the published treatment studies are in cells and mice, so months of human use is uncharted. What happens to weight after stopping a GLP-1 drug is covered in our page on what happens when you stop a GLP-1. And stacking several compounds makes it impossible to tell which one is doing anything, good or bad.

Stacks and blends: what people combine

Stacking is how the community tries to cover what a single compound does not, and no stack on this page has been tested as a combination. In the public X posts our MOTS-c summary analyzed, people describe running MOTS-c alongside GLP peptides, NAD+ and other compounds rather than alone. The apparent logic is to pair an appetite drug with a compound pitched as changing energy use rather than hunger. 5-Amino-1MQ carries a similar exercise-linked pitch; the 2024 paper was titled around NNMT inhibition that “mimics and boosts exercise-mediated improvements in muscle function in aged mice” (Dimet-Wiley et al., 2024). We found no published human study of any of these pairings, so every stack claim rests on the separate parts, and for the research compounds those parts were measured in mice.

How much do weight-loss peptides cost?

Costs range widely, and price says nothing about evidence. On the storefront linked in this page’s “Where it’s sold” card, list prices captured on October 12, 2026 were $242 a month for 5-Amino-1MQ on a one-month plan or $187 a month on a three-month plan, $619 or $565 a month for MOTS-c, and $172 or $127 a month for retatrutide. Those are listing prices on that date; we did not verify checkout prices or what each includes, such as the consultation. Branded semaglutide and tirzepatide costs depend on insurance and the maker’s self-pay programs, which our guide to GLP-1 cost without insurance walks through. Paying more for a compound with only mouse data does not buy more certainty.

What the community is saying about peptides for weight loss

Our Community Insights summary for MOTS-c analyzed 19 public posts on X from July 16 to 19, 2026. These are anecdotes, not evidence. We have not yet built a community dataset for 5-Amino-1MQ or retatrutide, so we do not characterize user reports for those beyond published journalism.

• MOTS-c as a stack ingredient. Posters describe running MOTS-c inside wider routines rather than alone, alongside NAD+, GHK-Cu, GLP peptides, pre-workout, fasting and cardio, and experimenting with timing around fasting and exercise.
• Energy claims. Many posts frame MOTS-c as a mitochondrial energy peptide; some report noticeable improvements, and one poster who expected to dismiss it revisited his verdict after a month of daily use.
• Skepticism. Others call it part of a hype cycle where people chase each new peptide, and the pairing with SS-31 is debated with no agreement on order or timing.
• Retatrutide on the gray market. Reporting in August 2026 described people using unapproved retatrutide after plateauing on tirzepatide or because they like being early, with doctors warning that buyers do not know what they are injecting (The Guardian, August 31, 2026).

Set against the research, the community runs ahead of the data. The MOTS-c energy stories attach to a compound with no completed human treatment trial, and the retatrutide buyers in the Guardian’s reporting are acting before any approval. The 2021 MOTS-c study showing exercise raises the body’s own MOTS-c (Reynolds et al., 2021) is a reminder that training itself raises it.

The bottom line

“Peptides for weight loss” is one search term covering a ladder of evidence. At the top are approved peptide drugs with large trials and known risks. Next is retatrutide, with striking but still unapproved results. At the bottom are MOTS-c and 5-Amino-1MQ, interesting lab compounds with no human weight-loss data. Before choosing anything, ask what species was studied, what outcome was measured and for how long, and talk it through with a clinician who knows your history.

Status: 5-Amino-1MQ: Not FDA-approved; sold by some telehealth providers as a compounded prescription. MOTS-c: Not FDA-approved; sold by some telehealth providers as a compounded prescription. An FDA advisory committee reportedly voted in July 2026 to recommend allowing pharmacies to compound it; nothing has changed yet. Retatrutide: Investigational; not FDA-approved. Lilly plans to submit it for approval in Q1 2027. What these status terms mean.

Educational information only, not medical advice. Every efficacy and safety statement on this page is sourced to the peer-reviewed literature, FDA drug labels, trial registries or company trial announcements linked above; the community summary reflects public posts on X analyzed in July 2026. Prices are a dated snapshot from October 12, 2026. Updated October 12, 2026. This page is drafted with AI assistance and fact-checked against the cited primary sources before publication.